5 research outputs found
Recent Advances in Health Biotechnology During Pandemic
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which
emerged in 2019, cut the epoch that will make profound fluctuates in the history of the world
in social, economic, and scientific fields. Urgent needs in public health have brought with
them innovative approaches, including diagnosis, prevention, and treatment. To exceed the
coronavirus disease 2019 (COVID-19) pandemic, various scientific authorities in the world
have procreated advances in real time polymerase chain reaction (RT-PCR) based diagnostic
tests, rapid diagnostic kits, the development of vaccines for immunization, and the purposing
pharmaceuticals for treatment. Diagnosis, treatment, and immunization approaches put for-
ward by scientific communities are cross-fed from the accrued knowledge of multidisciplinary
sciences in health biotechnology. So much so that the pandemic, urgently prioritized in the
world, is not only viral infections but also has been the pulsion in the development of novel
approaches in many fields such as diagnosis, treatment, translational medicine, virology, mi-
crobiology, immunology, functional nano- and bio-materials, bioinformatics, molecular biol-
ogy, genetics, tissue engineering, biomedical devices, and artificial intelligence technologies.
In this review, the effects of the COVID-19 pandemic on the development of various scientific
areas of health biotechnology are discussed
Výdeoendoscopýc retroperýtoneal lumbar sympathectomy for selected cases: a new technýque
No Abstract
Linezolid Alone and in Combination with Rifampicin Prevents Experimental Vascular Graft Infection Due to Methicillin-Resistant Staphylococcus aureus and Staphylococcus epidermidis
Background: In this report we describe the in vivo antibacterial activity of linezolid in an experimental graft infection model in rats and compare it with teicoplanin. The objective of this study was also to determine the effects of the interaction of linezolid when it was combined with rifampicin and test this effect against strains of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. Materials and methods: Graft infections were established in the subcutaneous tissue of 130 Wistar rats by implantation of Dacron grafts followed by a topical inoculation with 2 × 107 CFU of clinical isolates of MRSA and MRSE. The study included a control group and six groups for each of the staphylococcal strains: an inoculated group that did not receive any antibiotic prophylaxis, two inoculated groups that received intraperitoneal prophylaxis with teicoplanin or linezolid alone, an inoculated group that received rifampicin-soaked grafts, and two inoculated groups that received a combination prophylaxis consisting of intraperitoneal teicoplanin or linezolid and rifampicin-soaked grafts. Results: There was a reduction in the quantitative bacterial graft cultures in all prophylaxis groups when compared with inoculated control groups. There was not a statistically significant difference between linezolid and teicoplanin prophylaxis groups. The best results were obtained by a combination of rifampicin-soaked grafts with linezolid or teicoplanin. Conclusions: We found no evidence to suggest that linezolid differs from teicoplanin regarding effectiveness in the prevention of prosthetic vascular graft infection. Linezolid plus rifampicin and teicoplanin plus rifampicin are demonstrated to be valuable prophylactic regimens. © 2007 Elsevier Inc. All rights reserved
Linezolid alone and in combination with rifampicin prevents experimental vascular graft infection due to methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
BACKGROUND: In this report we describe the in vivo antibacterial activity of linezolid in an experimental graft infection model in rats and compare it with teicoplanin. The objective of this study was also to determine the effects of the interaction of linezolid when it was combined with rifampicin and test this effect against strains of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. MATERIALS AND METHODS: Graft infections were established in the subcutaneous tissue of 130 Wistar rats by implantation of Dacron grafts followed by a topical inoculation with 2 x 10(7) CFU of clinical isolates of MRSA and MRSE. The study included a control group and six groups for each of the staphylococcal strains: an inoculated group that did not receive any antibiotic prophylaxis, two inoculated groups that received intraperitoneal prophylaxis with teicoplanin or linezolid alone, an inoculated group that received rifampicin-soaked grafts, and two inoculated groups that received a combination prophylaxis consisting of intraperitoneal teicoplanin or linezolid and rifampicin-soaked grafts. RESULTS: There was a reduction in the quantitative bacterial graft cultures in all prophylaxis groups when compared with inoculated control groups. There was not a statistically significant difference between linezolid and teicoplanin prophylaxis groups. The best results were obtained by a combination of rifampicin-soaked grafts with linezolid or teicoplanin. CONCLUSIONS: We found no evidence to suggest that linezolid differs from teicoplanin regarding effectiveness in the prevention of prosthetic vascular graft infection. Linezolid plus rifampicin and teicoplanin plus rifampicin are demonstrated to be valuable prophylactic regimens
Cranial imaging findings in neurobrucellosis: results of Istanbul-3 study
Objective Neuroimaging abnormalities in central nervous system (CNS) brucellosis are not well documented. The purpose of this study was to evaluate the prevalence of imaging abnormalities in neurobrucellosis and to identify factors associated with leptomeningeal and basal enhancement, which frequently results in unfavorable outcomes